The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Targeting adenosine A2A receptors in Parkinson's disease
Open accessAbstract
The adenosine A2A receptor has emerged as an attractive non-dopaminergic target in the pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS distribution. It is highly enriched in striatopallidal neurons and can form functional heteromeric complexes with other G-protein-coupled receptors, including dopamine D2, metabotropic glutamate mGlu5 and adenosine A1 receptors. Blockade of the adenosine A2A receptor in striatopallidal neurons reduces postsynaptic effects of dopamine depletion, and in turn lessens the motor deficits of PD. A2A antagonists might partially improve not only the symptoms of PD but also its course, by slowing the underlying neurodegeneration and reducing the maladaptive neuroplasticity that complicates standard 'dopamine replacement' treatments. Thus, we review here a prime example of translational neuroscience, through which antagonism of A2A receptors has now entered the arena of clinical trials with realistic prospects for advancing PD therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Role and Regulation of Adenosine in the Central Nervous System
Dunwiddie, T. V., & Masino, S. A. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.31 · Cited by 1,632
Pathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 844
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., & Thiel, M. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104731 · Cited by 696
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90173-9 · Cited by 650
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00285.x · Cited by 641
Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
Self-citationCiruela, F., Casadó, V., Rodrigues, R. J., Luján, R., Burgueño, J., Canals, M., Borycz, J., Rebola, N., Goldberg, S. R., Mallol, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3574-05.2006 · Cited by 590
Schiffmann, S. N., Jacobs, O., & Vanderhaeghen, J. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08257.x · Cited by 530
Hillion, J., Canals, M., Torvinen, M., Casadó, V., Scott, R., Terasmaa, A., Hansson, A., Watson, S., Olah, M. E., Mallol, J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107731200 · Cited by 500
Self-citationAdenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization
Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S. R., Neve, K., Fuxe, K., Agnati, L. F., Woods, A. S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306451200 · Cited by 432
Self-citationFerré, S., Karcz-Kubicha, M., Hope, B. T., Popoli, P., Burgueño, J., Gutiérrez, M. A., Casadó, V., Fuxe, K., Goldberg, S. R., Lluis, C., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172393799 · Cited by 365
Self-citationKanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K. B., Nakamura, J., Kase, H., Kuwana, Y., & Jenner, P. (1998) · Annals of Neurology · doi:10.1002/ana.410430415 · Cited by 354
ACTIONS OF ADENOSINE AT ITS RECEPTORS IN THE CNS: Insights from Knockouts and Drugs
Fredholm, B. B., Chen, J.-F., Masino, S. A., & Vaugeois, J.-M. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095731 · Cited by 354
Self-citationAdenosine A 2A receptor antagonist treatment of Parkinson’s disease
Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., & Chase, T. N. (2003) · Neurology · doi:10.1212/01.wnl.0000073136.00548.d4 · Cited by 327
Agnati, L. F., Ferré, S., Lluis, C., Franco, R., & Fuxe, K. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.2 · Cited by 323
Self-citationRandomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD
Hauser, R. A., Hubble, J. P., Truong, D. D., & the Istradefylline US-001 Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000081227.84197.0b · Cited by 300
Chen, J.-F., Moratalla, R., Impagnatiello, F., Grandy, D. K., Cuellar, B., Rubinstein, M., Beilstein, M. A., Hackett, E., Fink, J. S., Low, M. J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1970 · Cited by 256
Self-citationNeuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity
Dall'lgna, O. P., Porciúncula, L. O., Souza, D. O., Cunha, R. A., & Lara, D. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705185 · Cited by 254
The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain
Ferre, S., O'Connor, W., Fuxe, K., & Ungerstedt, U. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-12-05402.1993 · Cited by 251
Self-citationAntiparkinsonian effect of a new selective adenosine A2Areceptor antagonist in MPTP-treated monkeys
Grondin, R., Bédard, P. J., Tahar, A. H., Grégoire, L., Mori, A., & Kase, H. (1999) · Neurology · doi:10.1212/wnl.52.8.1673 · Cited by 249
Fuxe, K., Agnati, L. F., Jacobsen, K., Hillion, J., Canals, M., Torvinen, M., Tinner-Staines, B., Staines, W., Rosin, D., Terasmaa, A., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000095206.44418.5c · Cited by 248
Self-citationTherapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
Xu, K., Bastia, E., & Schwarzschild, M. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.007 · Cited by 244
Self-citationAdenosine A2A and Dopamine D2 Heteromeric Receptor Complexes and Their Function
Fuxe, K., Ferré, S., Canals, M., Torvinen, M., Terasmaa, A., Marcellino, D., Goldberg, S. R., Staines, W., Jacobsen, K. X., Lluis, C., et al. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:26:2-3:209 · Cited by 235
Self-citationCaffeine, postmenopausal estrogen, and risk of Parkinson’s disease
Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., & Speizer, F. E. (2003) · Neurology · doi:10.1212/01.wnl.0000046523.05125.87 · Cited by 234
Self-citationCyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors
Fiebich, B. L., Biber, K., Lieb, K., Van Calker, D., Berger, M., Bauer, J., & Gebicke-Haerter, P. J. (1996) · Glia · doi:10.1002/(sici)1098-1136(199610)18:2<152::aid-glia7>3.0.co;2-2 · Cited by 225
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
Ikeda, K., Kurokawa, M., Aoyama, S., & Kuwana, Y. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00694.x · Cited by 224
Bibbiani, F., Oh, J. D., Petzer, J. P., Castagnoli, N., Chen, J.-F., Schwarzschild, M. A., & Chase, T. N. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00250-4 · Cited by 204
Self-citationMonopoli, A., Lozza, G., Forlani, A., Mattavelli, A., & Ongini, E. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00034 · Cited by 200
Yacoubi, M. E., Ledent, C., Parmentier, M., Bertorelli, R., Ongini, E., Costentin, J., & Vaugeois, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704240 · Cited by 199
Rodrigues, R. J., Alfaro, T. M., Rebola, N., Oliveira, C. R., & Cunha, R. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02887.x · Cited by 196
Aoyama, S., Kase, H., & Borrelli, E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05848.2000 · Cited by 180
Expression of Dopamine D3 Receptor Dimers and Tetramers in Brain and in Transfected Cells
Nimchinsky, E. A., Hof, P. R., Janssen, W. G. M., Morrison, J. H., & Schmauss, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29229 · Cited by 168
Lundblad, M., Vaudano, E., & Cenci, M. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01632.x · Cited by 168
Canals, M., Burgueño, J., Marcellino, D., Cabello, N., Canela, E. I., Mallol, J., Agnati, L., Ferré, S., Bouvier, M., Fuxe, K., et al. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02200.x · Cited by 159
Self-citationPhillis, J. W. (1995) · Brain Research · doi:10.1016/0006-8993(95)01153-6 · Cited by 159
Fenu, S., Pinna, A., Ongini, E., & Morelli, M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00944-2 · Cited by 153
Self-citationXu, K., Xu, Y., Brown-Jermyn, D., Chen, J., Ascherio, A., Dluzen, D. E., & Schwarzschild, M. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3008-05.2006 · Cited by 146
Self-citationMori, A., Shindou, T., Ichimura, M., Nonaka, H., & Kase, H. (1996) · Advances in behavioral biology · doi:10.1007/978-1-4899-0194-1_13 · Cited by 142
Pinna, A., Chiara, G. D., Wardas, J., & Morelli, M. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01285.x · Cited by 140
Self-citationMori, A., Shindou, T., Ichimura, M., Nonaka, H., & Kase, H. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00605.1996 · Cited by 140
Yu, L., Huang, Z., Mariani, J., Wang, Y., Moskowitz, M. A., & Chen, J. (2004) · Nature Medicine · doi:10.1038/nm1103 · Cited by 139
Self-citationOligomerization of adenosine A2A and dopamine D2 receptors in living cells
Kamiya, T., Saitoh, O., Yoshioka, K., & Nakata, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00991-4 · Cited by 138
Popoli, P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00256-1 · Cited by 136
Correa, M., Wisniecki, A., Betz, A. J., Dobson, D., O‘Neill, M. F., O’Neill, M. J., & Salamone, J. D. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00178-5 · Cited by 135
Torvinen, M., Marcellino, D. J., Canals, M., Agnati, L. F., Lluís, C., Franco, R., & Fuxé, K. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003376 · Cited by 134
Self-citationKachroo, A., Orlando, L. R., Grandy, D. K., Chen, J., Young, A. B., & Schwarzschild, M. A. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3660-05.2005 · Cited by 134
Self-citationMetabotropic mGlu5 receptors regulate adenosine A 2A receptor signaling
Nishi, A., Liu, F., Matsuyama, S., Hamada, M., Higashi, H., Nairn, A. C., & Greengard, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237126100 · Cited by 134
Persistent Behavioral Sensitization to Chronic l-DOPA Requires A2AAdenosine Receptors
Fredduzzi, S., Moratalla, R., Monopoli, A., Cuéllar, B., Xu, K., Ongini, E., Impagnatiello, F., Schwarzschild, M. A., & Chen, J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-03-01054.2002 · Cited by 128
Self-citationOchi, M., Koga, K., Kurokawa, M., Kase, H., Nakamura, J., & Kuwana, Y. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00250-5 · Cited by 128
Moine, C. L., Svenningsson, P., Fredholm, B. B., & Bloch, B. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-20-08038.1997 · Cited by 124
Jones, P. A., Smith, R. A., & Stone, T. W. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00540-x · Cited by 122
Coccurello, R., Breysse, N., & Amalric, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300444 · Cited by 120
Dı́az-Cabiale, Z., Vivó, M., Arco, A. D., O'Connor, W. T., Harte, M., Müller, C. E., Martı́nez, E., Popoli, P., Fuxé, K., & Ferré, S. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00179-9 · Cited by 117
Blum, D. L., Galas, M., Pintor, A., Brouillet, E., Ledent, C. A., Müller, C. E., Bantubungi, K., Galluzzo, M., Gall, D., Cuvelier, L., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05361.2003 · Cited by 116
Pinna, A., Fenu, S., & Morelli, M. (2001) · Synapse · Cited by 110
Self-citationXu, K., Xu, Y., Chen, J., & Schwarzschild, M. A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00069-1 · Cited by 105
Self-citationWardas, J., Konieczny, J., & Lorenc‐Koci, E. (2001) · Synapse · doi:10.1002/syn.1070 · Cited by 105
Ferré, S., & Fuxé, K. (1992) · Brain Research · doi:10.1016/0006-8993(92)91036-e · Cited by 103
Atlas of Neuroactive Substances and Their Receptors in the Rat
遠山, 正., 高辻, 功., & Kantha, S. S. (1998) · Oxford University Press eBooks · Cited by 97
Marchi, M., Raiteri, L., Risso, F., Vallarino, A., Bonfanti, A., Monopoli, A., Ongini, E., & Raiteri, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704712 · Cited by 96
Adenosine enhances glial glutamate efflux via A2a adenosine receptors
Li, X. X., Nomura, T., Aihara, H., & Nishizaki, T. (2001) · Life Sciences · doi:10.1016/s0024-3205(00)01036-5 · Cited by 96
KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse
Pierri, M., Vaudano, E., Sager, T. N., & Englund, U. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.009 · Cited by 94
Pollack, A. E., & Fink, J. S. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00168-i · Cited by 93
Marchi, M., Raiteri, L., Risso, F., Vallarino, A., Bonfanti, A., Monopoli, A., Ongini, E., & Raiteri, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704857 · Cited by 91
Atlas of Neuroactive Substances and Their Receptors in the Rat
Tohyama, M., & Takatsuji, K. (1998) · Cited by 88
Ferré, S., Popoli, P., Rimondini, R., Reggio, R., Kehr, J., & Fuxe, K. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00154-3 · Cited by 81
Self-citationStriatal glutamatergic mechanisms and extrapyramidal movement disorders
Chase, T. N., Bibbiani, F., & Oh, J. D. (2003) · Neurotoxicity Research · doi:10.1007/bf03033378 · Cited by 78
Agnati, L. F., Tarakanov, A. O., Ferré, S., Fuxé, K., & Guidolin, D. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:26:2-3:193 · Cited by 73
Self-citationAlfinito, P. D., Wang, S.-P., Manzino, L., Rijhsinghani, S., Zeevalk, G. D., & Sonsalla, P. K. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10982.2003 · Cited by 72
Fink, J. S., Kalda, A., Ryu, H., Stack, E. C., Schwarzschild, M. A., Chen, J., & Ferrante, R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02145.x · Cited by 68
Self-citationPollack, A. E., & Fink, J. S. (1996) · Brain Research · doi:10.1016/s0006-8993(96)01036-0 · Cited by 67
Fuxé, K., Ferré, S., Snaprud, P., von Euler, G., Johansson, B. A., & Ferdholm, B. (1993) · Drug Development Research · doi:10.1002/ddr.430280334 · Cited by 53
Pinna, A., Pontis, S., & Morelli, M. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.03.021 · Cited by 40
Self-citationAdenosine A 2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats
Carta, A. R., Pinna, A., Tronci, E., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000095210.55600.9c · Cited by 20
Cited by
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Dichotomous dopaminergic control of striatal synaptic plasticity
Shen, W., Flajolet, M., Greengard, P., & Surmeier, D. J. (2008) · Science · doi:10.1126/science.1160575 · Cited by 1,190
Surmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Metadata
- Authors
- Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J.-F., & Morelli, M.
- Venue
- Trends in Neurosciences
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 29
- Issue
- 11
- Pages
- 647-654
- ISSN
- 0166-2236 (ISSN-L)
- OpenAlex
- W1987380827
- Cited by
- 433
- References
- 76
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.